Radiological Features for Outcomes of MOGAD in Children: A Cohort in Southwest China

References

• Satukijchai C, Mariano R, Messina S, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open. 2022;5(1):e2142780. doi:10.1001/jamanetworkopen.2021.42780
   Web of Science ®Google Scholar
• Fadda G, Banwell B, Waters P, et al. Silent new brain MRI lesions in children with MOG-antibody associated disease. Ann Neurol. 2021;89(2):408–413. doi:10.1002/ana.25957
   Web of Science ®Google Scholar
• Reindl M, Jarius S, Rostasy K, et al. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol. 2017;30(3):295–301. doi:10.1097/WCO.0000000000000446
   Web of Science ®Google Scholar
• Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e62. doi:10.1212/NXI.0000000000000062
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Dornmair K, Meinl E, et al. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. 2016;15(3):317–331. doi:10.1016/S1474-4422(15)00313-0
   PubMed Web of Science ®Google Scholar
• Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89–102. doi:10.1038/s41582-018-0112-x
   PubMed Web of Science ®Google Scholar
• Immunology N B O T C S O. Chinese expert consensus on diagnosis and treatment of MOG-IgG associated disorders. Chin J Neuroimmunol Neurol. 2020;27(2):86–94.
   Google Scholar
• Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis. 2013;19(10):1261–1267. doi:10.1177/1352458513484547
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Rossor T, Mankad K, et al. ‘Leukodystrophy-like’ phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child Neurol. 2018;60(4):417–423. doi:10.1111/dmcn.13649
   Web of Science ®Google Scholar
• Gardinier MV, Amiguet P, Linington C, et al. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res. 1992;33(1):177–187. doi:10.1002/jnr.490330123
   Web of Science ®Google Scholar
• Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8. doi:10.1186/1742-2094-8-184
   Web of Science ®Google Scholar
• Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: part 1 - classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:2–13.
   Web of Science ®Google Scholar
• Pröbstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77(6):580–588. doi:10.1212/WNL.0b013e318228c0b1
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(Pt 7):1863–1874. doi:10.1093/brain/awv105
   PubMed Web of Science ®Google Scholar
• Balfour HH, Sifakis F, Sliman JA, et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–1293. doi:10.1093/infdis/jit321
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89(3):269–278. doi:10.1212/WNL.0000000000004117
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–3138. doi:10.1093/brain/awx276
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e69. doi:10.1212/WNL.0000000000005560
   PubMed Web of Science ®Google Scholar
• Juryńczyk M, Jacob A, Fujihara K, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol. 2019;19(3):187–195. doi:10.1136/practneurol-2017-001787
   Google Scholar
• Hino-Fukuyo N, Haginoya K, Nakashima I, et al. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Brain Dev. 2015;37(9):849–852. doi:10.1016/j.braindev.2015.02.006
   Web of Science ®Google Scholar
• Tsuburaya RS, Miki N, Tanaka K, et al. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis. Brain Dev. 2015;37(1):145–148. doi:10.1016/j.braindev.2014.02.002
   Web of Science ®Google Scholar
• Ramberger M, Bsteh G, Schanda K, et al. NMDA receptor antibodies: a rare association in inflammatory demyelinating diseases. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e141. doi:10.1212/NXI.0000000000000141
   Google Scholar
• Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411–428. doi:10.1002/ana.24117
   PubMed Web of Science ®Google Scholar
• Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e322. doi:10.1212/NXI.0000000000000322
   PubMed Web of Science ®Google Scholar
• Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):534–536. doi:10.1136/jnnp-2016-315094
   PubMed Web of Science ®Google Scholar
• Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75(1):65–71. doi:10.1001/jamaneurol.2017.3196
   PubMed Web of Science ®Google Scholar
• Wang L, Zhangbao J, Zhou L, et al. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. Eur J Neurol. 2019;26(1):168–174. doi:10.1111/ene.13790
   PubMed Web of Science ®Google Scholar
• Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244–252. doi:10.1038/nature09614
   PubMed Web of Science ®Google Scholar
• Messina S, Mariano R, Roca-Fernandez A, et al. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Multiple Sclerosis. 2022;28(2):217–227. doi:10.1177/13524585211018987
   Web of Science ®Google Scholar
• Fadda G, Waters P, Woodhall M, et al. Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis. 2022;13524585221093789. doi:10.1177/13524585221093789
   Web of Science ®Google Scholar
• Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617–627. doi:10.1093/brain/aww350
   PubMed Web of Science ®Google Scholar
• Patel J, Pires A, Derman A, et al. Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI. J Clin Neurosci. 2022;101:32–36. doi:10.1016/j.jocn.2022.04.035
   Web of Science ®Google Scholar
• Jarius S, Metz I, König FB, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Multiple Sclerosis. 2016;22(12):1541–1549. doi:10.1177/1352458515622986
   PubMed Web of Science ®Google Scholar
• Baumann M, Grams A, Djurdjevic T, et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol. 2018;265(4):845–855. doi:10.1007/s00415-018-8781-3
   Web of Science ®Google Scholar
• Tantsis EM, Prelog K, Alper G, et al. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. Dev Med Child Neurol. 2019;61(9):1108–1116. doi:10.1111/dmcn.14114
   Web of Science ®Google Scholar
• Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301–309. doi:10.1001/jamaneurol.2018.4053
   PubMed Web of Science ®Google Scholar
• Fadda G, Alves CA, O’mahony J, et al. Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes. JAMA Netw Open. 2021;4(10):e2128871. doi:10.1001/jamanetworkopen.2021.28871
   Web of Science ®Google Scholar